WOODBRIDGE, ON,
May 13, 2014 /PRNewswire/ -
Pivotal Therapeutics Inc. (OTCQX: PVTTF) (CSE: PVO), a
specialty pharmaceutical company with a focus on Omega-3 therapies
for cardiovascular disease (CVD) and overall health, announced that
it has engaged Brandkarma LLC., an award winning, US-based,
healthcare marketing and brand specialist with global expertise to
support the Company's commercialization strategy for
VASCAZEN®.
"VASCAZEN® represents a
much-needed solution for Omega-3 deficiency. Healthcare providers
and the general public at large need to know the serious health
risks associated with this deficiency. We are proud to be a part of
the team tasked with bringing this brand to the market," stated
Ken Ribotsky, President and CEO of
Brandkarma. Brandkarma's client list includes some of the largest
healthcare companies in the world and has established itself as a
leader in the medical food arena.
"We are very excited to have Brandkarma as our
marketing partner," stated Ms. Rachelle
MacSweeney, President and COO. "With the closing of
the financing on March 4, Pivotal
finally has the resources to execute its marketing plan and
implement its strategy to effectively penetrate US market
opportunities for VASCAZEN®. We would also like
to thank our investors and shareholders for their continued support
and patience as we embark on this next stage of commercialization
and make VASCAZEN® a success," added Ms.
Rachelle MacSweeney, President and
COO.
About VASCAZEN®
VASCAZEN® is currently available
in the U.S. as a prescription only medical food specifically
formulated for the dietary management of an Omega-3 deficiency in
cardiovascular patients. VASCAZEN® is a >90%
pure Omega-3 with a proprietary 6:1 EPA:DHA fatty acid formulation,
protected by a series of both U.S. and foreign patents.
VASCAZEN® has been clinically
shown to correct an Omega-3 deficiency within eight weeks of
treatment with positive concomitant effects on the lipid profiles,
mainly a 48% reduction of triglycerides and an increase of HDL
without negative impact on the LDL-C lipid profile.
VASCAZEN®'s results were achieved with a dose of
3 grams of EPA and DHA per day of a prescription grade, high purity
Omega-3.
About Brandkarma LLC.
Brandkarma LLC. is a strategic marketing consulting
and healthcare communications company for specialty pharmaceutical,
biotech, medical device, diagnostic and health service
companies. Clients collaborate with Brandkarma's highly
specialized and experienced strategists to tackle everything from
brand (re)positioning and market landscaping to strategic and
creative brand development, advertising and promotion, sales force
programs, corporate communications, corporate identity, digital and
social media, and public relations. Learn more about Brandkarma at
the award-winning website brandkarma.org.
About Pivotal Therapeutics Inc.
Pivotal Therapeutics is a publicly traded
(OTCQX: PVTTF) (CSE: PVO) specialty pharmaceutical company with a
focus on cardiovascular disease and overall health. Pivotal
Therapeutics' lead product VASCAZEN® is a
prescription only medical food formulated to meet the dietary
Omega-3 deficient needs of patients with cardiovascular disease
through elevating Eicosapentaenoic acid (EPA) and Docosahexaenoic
acid (DHA) to levels associated with reduced risk of cardiovascular
complications. OMAZEN® is a pharmaceutical grade
Omega-3 providing over 90% pure Omega-3 in each capsule for the
maintenance of good health. OMAZEN® is a patented
product available for sale and distribution in Canada
Disclosure Notice
The information contained in this document is as of May 13, 2014. This press release contains
forward-looking statements. Such forward-looking statements are
subject to a number of risks, assumptions and uncertainties that
could cause Pivotal's actual results to differ materially from
those projected in such forward-looking statements. These
statements can be identified by the use of words such as "will",
"anticipate", "estimate", "expect", "project", "forecast",
"intend", "plan", "believe", "project", "potential", and similar
expressions with any discussion of future operating or financial
performance or events. In particular, factors that could cause
actual results to differ materially from those in forward looking
statements include the following: Pivotal's inability to obtain
additional financing on acceptable terms; growth in costs and
expenses; inability to compete with others who provide comparable
products; risk that the Company's products will not gain widespread
market acceptance; risks relating to the Company's ability to
maintain its CSE listing. Forward-looking statements speak only as
of the date made and are not guarantees of future performance. The
Company undertakes no obligation to publicly update or revise any
forward-looking statements contained in this document as a result
of new information or future events or developments. CSE has not
reviewed and does not accept responsibility for the adequacy or
accuracy of this information.
SOURCE Pivotal Therapeutics Inc.
Image with caption: "VASCAZEN® a prescription only medical food
for the dietary management of an Omega 3 deficiency in
Cardiovascular patients. (CNW Group/Pivotal Therapeutics Inc.)".
Image available at:
http://photos.newswire.ca/images/download/20140513_C8112_PHOTO_EN_40243.jpg